Cas:221532-96-3 tert-butyl 4-[(4-aminophenyl)methyl]piperidine-1-carboxylate manufacturer & supplier

Chemical Name:tert-butyl 4-[(4-aminophenyl)methyl]piperidine-1-carboxylate

CAS.NO:221532-96-3

Synonyms:tert-butyl 4-[(4-aminophenyl)methyl]piperidine-1-carboxylate

Molecular Formula:C₁₇H₂₆N₂O₂

Molecular Weight:290.40100

HS Code:2933399090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:55.56000

Exact Mass:290.19900

LogP:3.97750

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like tert-butyl 4-[(4-aminophenyl)methyl]piperidine-1-carboxylate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,tert-butyl 4-[(4-aminophenyl)methyl]piperidine-1-carboxylate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,tert-butyl 4-[(4-aminophenyl)methyl]piperidine-1-carboxylate Use and application,tert-butyl 4-[(4-aminophenyl)methyl]piperidine-1-carboxylate technical grade,usp/ep/jp grade.

Related News: Brian McNamara, currently head of GSK’s consumer healthcare division, will continue to serve as the franchise’s CEO after it breaks away from GSK in 2022, the British pharma said Thursday. 5-Bromomethyl-3-ethoxy-4-methyl-isoxazole manufacturers The business, home to popular brands such as arthritis gel Voltaren and vitamins line Centrum, generated over £10 billion in sales during 2020. 1(3H)-Isobenzofuranone, 3-[(2-nitrophenyl)methylene]-, (Z)- suppliers CHMP on Friday also announced that Roche pulled its Tecentriq application in triple-negative breast cancer after it noted that the EMA said the results from a late-stage trial do not favor the drug’s benefit-risk calculation in this indication. N,N’-bis-(2-acetoxy-phenyl)-oxalamide vendor & factory Importance of evaluating biocatalytic processes during development,In Massachusetts, where the bulk of Takeda’s U.S. operations are based since the Shire buyout, the Japanese pharma has been swiftly ramping up its cell therapy ambitions. In September, the company cut the ribbon on a new 24,000-square-foot R&D manufacturing center in Boston, which it said at the time would handle clinical development for three ongoing pipeline programs and two other prospects pegged to enter clinical development by the end of 2021.